Pharmacokinetics and pharmacodynamics of oral β-lactam antibiotics as a two-dimensional approach to their efficacy

被引:26
作者
Auckenthaler, R
机构
[1] Unilabs SA, CH-1211 Geneva 1, Switzerland
[2] Univ Geneva, Geneva, Switzerland
关键词
D O I
10.1093/jac/dkf803
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Pharmacokinetic and pharmacodynamic parameters are increasingly recognized as important determinants of the therapeutic efficacy of an antibiotic. For beta-lactam antibiotics, the most important determinant of the antimicrobial efficacy, and hence predictor of therapeutic efficacy, is the length of time that serum concentrations exceed the MIC. Dosing schedules for beta-lactam antibiotics should maintain serum concentrations above the MIC for the bacterial pathogen for at least 50% of the dosing interval to achieve therapeutic efficacy and prevent the development of resistance. This is a basic criterion for the clinical efficacy of beta-lactams. A combination of microbiological activity and pharmacokinetic characteristics was applied to calculate the time that serum antibiotic concentrations exceed the MIC for the major respiratory tract pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pyogenes and Klebsiella pneumoniae. In contrast with some other oral beta-lactam antibiotics, cefpodoxime 200 mg bd maintains serum concentrations above the MIC for each organism for at least 50% of the dosing interval and may therefore be an attractive choice for empirical therapy of community-acquired lower respiratory tract infections.
引用
收藏
页码:13 / 17
页数:5
相关论文
共 20 条
[1]   Amoxycillin clavulanate: An assessment after 15 years of clinical application [J].
Ball, P ;
Geddes, A ;
Rolinson, G .
JOURNAL OF CHEMOTHERAPY, 1997, 9 (03) :167-198
[2]   EFFICACY AND SAFETY OF CEFPROZIL VERSUS OTHER BETA-LACTAM ANTIBIOTICS IN THE TREATMENT OF LOWER RESPIRATORY-TRACT INFECTIONS [J].
BALL, P .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (10) :851-856
[3]   Evolving resistance patterns of Streptococcus pneumoniae:: A link with long-acting macrolide consumption? [J].
Baquero, F .
JOURNAL OF CHEMOTHERAPY, 1999, 11 :35-43
[4]   ANTIBACTERIAL ACTIVITY OF CEFPODOXIME IN COMPARISON WITH CEFIXIME, CEFDINIR, CEFETAMET, CEFTIBUTEN, LORACARBEF, CEFPROZIL, BAY-3522, CEFUROXIME, CEFACLOR AND CEFADROXIL [J].
BAUERNFEIND, A ;
JUNGWIRTH, R .
INFECTION, 1991, 19 (05) :353-362
[5]   Cefaclor into the millennium [J].
Brumfitt, W ;
Hamilton-Miller, JMT .
JOURNAL OF CHEMOTHERAPY, 1999, 11 (03) :163-178
[6]   CEFPODOXIME PROXETIL VS CEFIXIME FOR PAINFUL FEBRILE ACUTE OTITIS-MEDIA IN CHILDREN [J].
COHEN, R ;
DELAROCQUE, F ;
BOUCHERAT, M ;
GRANDSENNE, P ;
CORRARD, F ;
BOUHANNA, CA ;
RICHOUX, F ;
LECOMPTE, MD ;
LASTMANN, C ;
PAPPO, A ;
COICADAN, L ;
WOLLNER, A ;
SCHLEMMER, C ;
ROBIN, M ;
KEMENY, G ;
BEDBEDER, P ;
BODIN, MJ ;
AZOULAY, M ;
GESLIN, P .
MEDECINE ET MALADIES INFECTIEUSES, 1994, 24 (8-9) :844-851
[7]   Antimicrobial resistance issues of the future [J].
Craig, WA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1996, 25 (04) :213-217
[8]   Re-evaluating current antibiotic therapy [J].
Craig, WA .
RESPIRATORY MEDICINE, 2001, 95 :S14-S21
[9]   Acute otitis media:: management and surveillance in an era of pneumococcal resistance -: a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group [J].
Dowell, SF ;
Butler, JC ;
Giebink, GS ;
Jacobs, MR ;
Jernigan, D ;
Musher, DM ;
Rakowsky, A ;
Schwartz, B .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (01) :1-9
[10]   The Alexander Project 1996-1997:: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections [J].
Felmingham, D ;
Grüneberg, RN .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (02) :191-203